INSIGHTS ON CELL & GENE OUTSOURCING ISSUES
EMPQ And Validation Support Services
A growing pharmaceutical/biotech company hired a global consulting firm for a project that required EMPQ services for qualification activities on a newly completed aseptic processing suite.
Formula For Pharmaceutical Logistics And Supply Chain Success In 2024
Join global logistics leaders for an in-depth analysis of the evolving pharmaceutical supply chain, exploring critical issues, emerging trends, and strategies for navigating the complexities of 2024.
Boost Drug Development Productivity With Contract Research Services
Find out how organ-on-a-chip contract research services are enabling the pharmaceutical industry to overcome the largest challenge in drug development—Eroom’s Law.
Contract Research Services For Drug Discovery And Development
Understand and predict human response earlier in the drug development process, and harness the advantages of Organ-on-a-Chip technology without needing to invest in capital equipment or train personnel.
Expert Partnership Contract Testing Services
Learn about our best-in-class, risk-mitigating solutions with technical and regulatory expertise to help you bring life-changing drugs to market .
Consolidating The Supply Chain For mRNA
Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.
What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry?
Novo Holdings, the parent company to Novo Nordisk, announced a deal last week to acquire Catalent, the global CDMO, at a value of $16.5bn. In the same breath, Novo Holdings announced they will sell three sites directly to Novo Nordisk, implying that the rest of the assets of the company will continue to operate as a stand-alone CDMO. This article unpacks the acquisition, discussing questions such as “what does it mean for customers?” and “does this deal reshape the CDMO market?”
Adopting Modular, Semi-Automated Approaches To Optimize CGT Development
There are a number of technology solutions that, when applied to a cell and gene therapy workflow, can streamline development and improve workflow integration.
Exploring The Landscape, Modalities, And Logistics Of CGTs
Explore the latest market trends and the nuances of various cell and gene therapy modalities, along with the logistical considerations necessary to safeguard product quality and safety.
The Ins And Outs Of In-House Manufacturing: Building A Cell & Gene Production Facility
Deciding whether to bring manufacturing in-house or outsource it to a partner can be a daunting decision, particularly as market forces continue to put pressure on small biotechs.